Skip to main content
Fig. 3 | Diabetology & Metabolic Syndrome

Fig. 3

From: Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study

Fig. 3

The probability of mortality and cardiovascular outcomes in the patients with diabetes mellitus and diabetic foot in the DPP4i-only group or insulin-only group versus the combined therapy group by propensity score matching. The effects of DPP4i-only (a) and insulin-only therapy (b) on major adverse cardiac events, nonfatal myocardial infarction, nonfatal stroke, cardiac death, death resulting from any cause, amputation and heart failure for admission were analyzed individually. DPP4i dipeptidyl peptidase-4 inhibitor, CI confidence interval

Back to article page